Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CFB | P00751 | 1/20 | 0.36 |
| ▸ | GALR3 | O60755 | 2/20 | 0.35 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090689 | 0.93 | HRH3 (0.49) | HRH3EPHX2CYP11B1CYP11B2HTR1D | |
| SCHEMBL10705219 | 0.84 | HTR1D (0.49) | HRH3EPHX2HTR1DHTR1BMAPK1 | |
| SCHEMBL918507 | 0.81 | KMT2A (0.41) | HTR1DMEN1KMT2ACFB | |
| SCHEMBL3971875 | 0.78 | CYP11B1 (0.42) | CYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL11891933 | 0.78 | HRH3 (0.52) | HRH3EPHX2 | |
| SCHEMBL26121408 | 0.78 | HRH3 (0.47) | HRH3EPHX2CYP11B1CYP11B2MEN1 | |
| SCHEMBL10701848 | 0.77 | HRH3 (0.46) | HRH3EPHX2CYP11B1CYP11B2MEN1 | |
| SCHEMBL593755 | 0.77 | LMNA (0.50) | HRH3EPHX2CYP11B1CYP11B2MEN1 | |
| SCHEMBL5540745 | 0.77 | GRIN2B (0.50) | MAPK1 | |
| SCHEMBL27978872 | 0.74 | EPHX2 (0.51) | HRH3EPHX2CYP11B1CYP11B2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0284552-A1 | 4-Benzyl-piperazinyl-hydrazones | CIBA-GEIGY AG (CH) | 1988-09-28 | — | — | EP | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0293054-A2 | Novel diglycidyl ethers of diphenolic alkanes and their use in curable compositions | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1988-11-30 | — | — | EP | disclosed |
| EP-0284552-A1 | 4-Benzyl-piperazinyl-hydrazones | CIBA-GEIGY AG (CH) | 1988-09-28 | — | — | EP | disclosed |
| US-4391642-A | SACCHARIDE, PHENOL | FOSECO INTERNATIONAL LIMITED (GB) | 1983-07-05 | — | — | US | disclosed |
| EP-0024392-B1 | ALKALI METAL SILICATE BINDER COMPOSITIONS | FOSECO INTERNATIONAL LIMITED (GB) | 1982-08-04 | — | — | EP | disclosed |
| EP-0024392-A1 | ALKALI METAL SILICATE BINDER COMPOSITIONS. | FOSECO INT (GB) | 1981-03-11 | — | — | EP | disclosed |
| WO-1980001768-A1 | ALKALI METAL SILICATE BINDER COMPOSITIONS | FOSECO INT (GB) | 1980-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HRH3 420/4885EPHX2 3662/4885CYP11B1 514/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | HRH3 538/4885EPHX2 3472/4885CYP11B1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.